EGFR and non-small cell lung carcinoma: Regardless of EGFR-TKIs used in the first- and second-line settings or maintenance treatment, the presence of mutated-EGFR indicated superior PFS or ORR compared to comparator for therapy of NSCLC in series of trials from the unselected population [20,33] to the superior population [34], and the EGFR mutation-positive population [4,5,7].